CalciMedica, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for illnesses caused by inflammatory and immunologic processes and direct cellular damage. Its lead product candidate comprises Auxora, an intravenous formulated small molecule calcium release-activated calcium (CRAC) channel inhibitors for the treatment of acute pancreatitis, asparaginase-induced pancreatic toxicity, and acute kidney injury, as well as severe COVID-19 pneumonia. The company also develops Auxora for the treatment of ulcerative colitis, traumatic brain injury, and allergic asthma; and oral CRAC channel inhibitors for use in chronic inflammatory and immunologic disease. The company is based in La Jolla, California.
तुलना करने के लिए मीट्रिक्स | CALC | क्षेत्र सेक्टर - संबंधित क्षेत्र की कंपनियों के व्यापक समूह से मेट्रिक्स का औसत हेल्थकेयर | संबंध संबंधCALCपीअर्सक्षेत्र | |
|---|---|---|---|---|
पी/ई अनुपात | −0.4x | −1.7x | −0.5x | |
PEG अनुपात | 0.01 | −0.04 | 0.00 | |
क़ीमत/बुक | −1.6x | 1.8x | 2.6x | |
क़ीमत / एलटीएम बिक्री | - | 7.6x | 3.2x | |
अपसाइड (विश्लेषक लक्ष्य) | - | 497.2% | 49.3% | |
उचित मूल्य अपसाइड | अनलॉक करें | 3.8% | 6.3% | अनलॉक करें |